Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network …
Objective To evaluate sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-
like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes at varying …
like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes at varying …
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors are effective antidiabetic
therapies in patients with type 2 diabetes mellitus and are associated with improved …
therapies in patients with type 2 diabetes mellitus and are associated with improved …
Empagliflozin in acute myocardial infarction: the EMMY trial
D von Lewinski, E Kolesnik, NJ Tripolt… - European heart …, 2022 - academic.oup.com
Aims Sodium–glucose co-transporter 2 inhibition reduces the risk of hospitalization for heart
failure and for death in patients with symptomatic heart failure. However, trials investigating …
failure and for death in patients with symptomatic heart failure. However, trials investigating …
Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction
CG Santos-Gallego, AP Vargas-Delgado… - Journal of the American …, 2021 - jacc.org
Background Large clinical trials established the benefits of sodium-glucose cotransporter 2
inhibitors in patients with diabetes and with heart failure with reduced ejection fraction …
inhibitors in patients with diabetes and with heart failure with reduced ejection fraction …
Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)
Background: Sodium-glucose cotransporter 2 inhibitors reduce the risk of heart failure
hospitalization and cardiovascular death in patients with heart failure and reduced ejection …
hospitalization and cardiovascular death in patients with heart failure and reduced ejection …
[HTML][HTML] Sotagliflozin in patients with diabetes and recent worsening heart failure
Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure or death from cardiovascular causes among patients with …
hospitalization for heart failure or death from cardiovascular causes among patients with …
[HTML][HTML] Sotagliflozin in patients with diabetes and chronic kidney disease
Background The efficacy and safety of sodium–glucose cotransporter 2 inhibitors such as
sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic …
sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic …
Effects of SGLT2 inhibitors on kidney and cardiovascular function
SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients
with or without type 2 diabetes and preserved or reduced kidney function from failing. The …
with or without type 2 diabetes and preserved or reduced kidney function from failing. The …
An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors
T Salvatore, R Galiero, A Caturano, L Rinaldi… - International Journal of …, 2022 - mdpi.com
Sodium-glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal
proximal tubule, an insulin-independent mechanism that plays a critical role in glycemic …
proximal tubule, an insulin-independent mechanism that plays a critical role in glycemic …
The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
B Xu, S Li, B Kang, J Zhou - Cardiovascular diabetology, 2022 - Springer
Type 2 diabetes mellitus (T2DM) is a chronic, complex metabolic disease characterized by
chronic hyperglycemia causing from insufficient insulin signaling because of insulin …
chronic hyperglycemia causing from insufficient insulin signaling because of insulin …